Ingredient
Berberine
A plant alkaloid with real glucose effects in trials and a bioavailability problem that undercuts most of them.
Berberine is an isoquinoline alkaloid found in barberry, goldenseal, and several plants used in traditional Chinese medicine. It appears in the published literature most often for blood glucose, and the trials are consistent enough that the effect is not in doubt — what is in doubt is whether any capsule you can buy delivers it.
What the trials measured
The pooled figures come from meta-analyses that enrolled almost entirely people with type 2 diabetes. That population limit is stated on every row below because it determines who the numbers apply to.
| Outcome | Effect | 95% CI | Trials | Grade |
|---|---|---|---|---|
| Fasting plasma glucose | −0.54 mmol/L | −0.77 to −0.30 | 28 trials, 2,313 people | B |
| Post-meal glucose | −0.94 mmol/L | −1.27 to −0.61 | Same pooled analysis | B |
Both rows are graded B rather than A for the same reason: the pooled populations were diagnosed patients, and a result in that group does not transfer to someone using berberine preventively. The full grading rule is on how we grade evidence.
Why the milligram number on the label misleads
Berberine is poorly absorbed. The French food safety agency’s assessment notes that in vivo studies report less than 1% oral bioavailability, which means the amount reaching circulation is a fraction of the amount swallowed.
This has a practical consequence that most product pages skip. A trial reporting 900–1,500 mg per day was dosing a compound that mostly stayed in the gut. A supplement label printing 500 mg per capsule is not describing the same exposure unless the formulation includes an absorption strategy — and the label rarely says whether it does.
Dose ranges actually used in research
The most common studied dose is 0.9–1.5 g per day, split across two to four doses, typically over cycles of one to three months. Some trials have used as little as 50 mg and as much as 6,350 mg per day, but that spread reflects different conditions rather than a menu of equally good options.
Doses above the studied range are associated with gastrointestinal upset, cramping, and diarrhea, which is the main reason products advise splitting the dose and taking it with food.
What a label has to disclose to be comparable
Three fields decide whether a bottle can be matched to any row above:
The per-ingredient amount must be printed. A proprietary blend listing berberine among several ingredients with one combined weight cannot be compared with a trial, because the trial dose is not recoverable from it. The rule behind that gap is set out in what a Supplement Facts panel is required to omit.
The form must be named. Berberine HCl, berberine sulfate, and a whole-plant extract are not interchangeable, and the trials mostly used HCl.
The absorption claim, if made, must be specific. “Enhanced bioavailability” without naming the mechanism is a marketing statement, not a specification.
Safety notes that belong here
Berberine interacts with drugs metabolised by CYP3A4, CYP2D6, and CYP2C9, and it adds to the effect of glucose-lowering medication. Both are reasons a prescriber should know before it is added to a regimen. It is not recommended during pregnancy or lactation.
Where to read further
The dose question is worked through in detail in berberine dosage, including why the salt form on the label matters less than the milligram figure. The trial base is reviewed in berberine and blood sugar. The head-to-head comparison, and the limits of comparing a supplement to a prescription drug, are in berberine vs metformin. For a table of every measured outcome we have verified, see the trial effect sizes reference.
Facts checked: 29 October 2026 · VitalRoundup Editorial Team · How we review